ArticleBMC gastroenterology2026
Genetic and functional characterization of a novel SERPIND1 variant in a family with isolated gastric varices and venous thrombosis.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundIsolated gastric varices type I (IGV1) is a rare but severe manifestation of splenic vein thrombosis. While thrombophilia is a recognized cause, the underlying genetic determinants are often elusive. This study investigates the case of a proband presenting with IGV1, deep vein thrombosis (DVT), and Long QT syndrome Type 2 (LQT2), aiming to elucidate the genetic basis and functional impact of the identified SERPIND1 variants.
methodsWhole-exome sequencing identified candidate variants in the proband, which were validated by Sanger sequencing. Functional assessment included quantifying SERPIND1 and KCNH2 mRNA in proband and control blood, analyzing heparin cofactor Ⅱ (HCⅡ) protein expression and localization in transfected 293T cells, and predicting the potential structural consequences of the variants using bioinformatic tools.
resultsThe proband, a 31-year-old female, presented with isolated gastric fundal varices and a history of deep venous thrombosis (DVT), along with long QT syndrome type 2 (LQT2). Whole-exome sequencing (WES) identified two heterozygous variants, both confirmed by Sanger sequencing: a de novo SERPIND1 c.940 C > T (p.Arg314Trp) variant, classified as Pathogenic according to ACMG guidelines (PS2, PS3, PM2_Supporting, PP3), and a KCNH2 c.1707 C > A (p.Tyr569*) variant, also classified as Pathogenic (PVS1, PP1, PM2_Supporting) and showing familial co-segregation. The SERPIND1 variant was associated with reduced HCⅡ antigen levels and activity in plasma. In vitro assays revealed that both variants led to significantly reduced SERPIND1 and KCNH2 mRNA expression. In transfected cells, the SERPIND1 p.Arg314Trp variant markedly decreased HCⅡ protein levels and possibly induced aberrant nuclear mislocalization. Structural modeling suggested that the Arg314Trp substitution disrupts a key hydrogen bond within HCⅡ, while the KCNH2 p.Tyr569* nonsense variant is predicted to generate a truncated protein.
conclusionThe SERPIND1 c.940 C > T (p.Arg314Trp) variant is associated with reduced HCⅡ expression and functional impairment, which may contribute to a prothrombotic tendency in this patient. This study provides a hypothesis-generating observation supporting a potential role of HCⅡ deficiency in venous thrombosis and IGV1. The KCNH2 variant was accounted for the coexisting LQT2 phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.